Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a combination of two anticancer medicines,
called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These
medications will be tested at different dose levels. The investigators want to find out what
effects, good and/or bad, it has on patients and their recurrent lymphoma. The first two
drugs, vorinostat and niacinamide, suppress survival signals that lymphoma cells depend on.
The third drug, etoposide can kill sensitive lymphoma cells alone or in combination with
other chemotherapy drugs. Vorinostat is an anticancer agent that been approved by the Food
and Drug Administration for use in cutaneous T-cell lymphoma. It is being evaluated in this
study in combination with other anticancer medicines for use in other types of lymphoma.
Vorinostat's use in combination with anticancer regimens is experimental. Niacinamide is a
vitamin that is investigational or experimental when given at high doses as an anticancer
agent. Niacinamide has not yet been approved by the Food and Drug Administration for use in
lymphoma. Etoposide has been approved by the Food and Drug Administration for use in
aggressive non-Hodgkin's lymphoma. However, the way it will be given in this clinical study
is experimental.